The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 Infection
The aim of this study was to evaluate the performances of three commercially available antibody assays for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies at different time points following SARS-CoV-2 infection. Sera from 536 cases, including 207 SARS-CoV-2 P...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/10/2196 |
| _version_ | 1797469633538686976 |
|---|---|
| author | Heidi Syre Marius Eduardo Brå Obreque Ingvild Dalen Åse Garløv Riis Åse Berg Iren Høyland Löhr Jon Sundal Lars Kåre Kleppe May Sissel Vadla Ole Bernt Lenning Jan Stefan Olofsson Kristin Greve-Isdahl Mohn Camilla Tøndel Bjørn Blomberg Mai Chi Trieu Nina Langeland Rebecca Jane Cox |
| author_facet | Heidi Syre Marius Eduardo Brå Obreque Ingvild Dalen Åse Garløv Riis Åse Berg Iren Høyland Löhr Jon Sundal Lars Kåre Kleppe May Sissel Vadla Ole Bernt Lenning Jan Stefan Olofsson Kristin Greve-Isdahl Mohn Camilla Tøndel Bjørn Blomberg Mai Chi Trieu Nina Langeland Rebecca Jane Cox |
| author_sort | Heidi Syre |
| collection | DOAJ |
| description | The aim of this study was to evaluate the performances of three commercially available antibody assays for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies at different time points following SARS-CoV-2 infection. Sera from 536 cases, including 207 SARS-CoV-2 PCR positive, were tested for SARS-CoV-2 antibodies with the Wantai receptor binding domain (RBD) total antibody assay, Liaison S1/S2 IgG assay and Alinity i nucleocapsid IgG assay and compared to a two-step reference ELISA (SARS-CoV-2 RBD IgG and SARS-CoV-2 spike IgG). Diagnostic sensitivity, specificity, predictive values and Cohen’s kappa were calculated for the commercial assays. The assay’s sensitivities varied greatly, from 68.7% to 95.3%, but the specificities remained high (96.9–99.1%). The three tests showed good performances in sera sampled 31 to 60 days after PCR positivity compared to the reference ELISA. The total antibody test performed better than the IgG tests the first 30 days and the nucleocapsid IgG test showed reduced sensitivity two months or more after PCR positivity. Hence, the test performances at different time points should be taken into consideration in clinical practice and epidemiological studies. Spike or RBD IgG tests are preferable in sera sampled more than two months following SARS-CoV-2 infection. |
| first_indexed | 2024-03-09T19:22:54Z |
| format | Article |
| id | doaj.art-67c7288cb9a746579661256b12606ed2 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T19:22:54Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-67c7288cb9a746579661256b12606ed22023-11-24T03:09:10ZengMDPI AGViruses1999-49152022-10-011410219610.3390/v14102196The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 InfectionHeidi Syre0Marius Eduardo Brå Obreque1Ingvild Dalen2Åse Garløv Riis3Åse Berg4Iren Høyland Löhr5Jon Sundal6Lars Kåre Kleppe7May Sissel Vadla8Ole Bernt Lenning9Jan Stefan Olofsson10Kristin Greve-Isdahl Mohn11Camilla Tøndel12Bjørn Blomberg13Mai Chi Trieu14Nina Langeland15Rebecca Jane Cox16Department of Medical Microbiology, Stavanger University Hospital, 4068 Stavanger, NorwayDepartment of Medical Microbiology, Stavanger University Hospital, 4068 Stavanger, NorwayDepartment of Research, Section of Biostatistics, Stavanger University Hospital, 4068 Stavanger, NorwayDepartment of Medicine, Stavanger University Hospital, 4068 Stavanger, NorwayDepartment of Medicine, Stavanger University Hospital, 4068 Stavanger, NorwayDepartment of Medical Microbiology, Stavanger University Hospital, 4068 Stavanger, NorwayDepartment of Medicine, Stavanger University Hospital, 4068 Stavanger, NorwayDepartment of Medicine, Stavanger University Hospital, 4068 Stavanger, NorwayMunicipality of Randaberg, 4070 Randaberg, NorwayMunicipality of Randaberg, 4070 Randaberg, NorwayInfluenza Centre, Department of Clinical Science, University of Bergen, 5007 Bergen, NorwayInfluenza Centre, Department of Clinical Science, University of Bergen, 5007 Bergen, NorwayInfluenza Centre, Department of Clinical Science, University of Bergen, 5007 Bergen, NorwayDepartment of Clinical Science, University of Bergen, 5007 Bergen, NorwayInfluenza Centre, Department of Clinical Science, University of Bergen, 5007 Bergen, NorwayDepartment of Clinical Science, University of Bergen, 5007 Bergen, NorwayInfluenza Centre, Department of Clinical Science, University of Bergen, 5007 Bergen, NorwayThe aim of this study was to evaluate the performances of three commercially available antibody assays for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies at different time points following SARS-CoV-2 infection. Sera from 536 cases, including 207 SARS-CoV-2 PCR positive, were tested for SARS-CoV-2 antibodies with the Wantai receptor binding domain (RBD) total antibody assay, Liaison S1/S2 IgG assay and Alinity i nucleocapsid IgG assay and compared to a two-step reference ELISA (SARS-CoV-2 RBD IgG and SARS-CoV-2 spike IgG). Diagnostic sensitivity, specificity, predictive values and Cohen’s kappa were calculated for the commercial assays. The assay’s sensitivities varied greatly, from 68.7% to 95.3%, but the specificities remained high (96.9–99.1%). The three tests showed good performances in sera sampled 31 to 60 days after PCR positivity compared to the reference ELISA. The total antibody test performed better than the IgG tests the first 30 days and the nucleocapsid IgG test showed reduced sensitivity two months or more after PCR positivity. Hence, the test performances at different time points should be taken into consideration in clinical practice and epidemiological studies. Spike or RBD IgG tests are preferable in sera sampled more than two months following SARS-CoV-2 infection.https://www.mdpi.com/1999-4915/14/10/2196SARS-CoV-2antibody assayspikereceptor binding domainnucleocapsid |
| spellingShingle | Heidi Syre Marius Eduardo Brå Obreque Ingvild Dalen Åse Garløv Riis Åse Berg Iren Høyland Löhr Jon Sundal Lars Kåre Kleppe May Sissel Vadla Ole Bernt Lenning Jan Stefan Olofsson Kristin Greve-Isdahl Mohn Camilla Tøndel Bjørn Blomberg Mai Chi Trieu Nina Langeland Rebecca Jane Cox The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 Infection Viruses SARS-CoV-2 antibody assay spike receptor binding domain nucleocapsid |
| title | The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 Infection |
| title_full | The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 Infection |
| title_fullStr | The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 Infection |
| title_full_unstemmed | The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 Infection |
| title_short | The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 Infection |
| title_sort | performances of three commercially available assays for the detection of sars cov 2 antibodies at different time points following sars cov 2 infection |
| topic | SARS-CoV-2 antibody assay spike receptor binding domain nucleocapsid |
| url | https://www.mdpi.com/1999-4915/14/10/2196 |
| work_keys_str_mv | AT heidisyre theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT mariuseduardobraobreque theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT ingvilddalen theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT asegarløvriis theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT aseberg theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT irenhøylandlohr theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT jonsundal theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT larskarekleppe theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT maysisselvadla theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT oleberntlenning theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT janstefanolofsson theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT kristingreveisdahlmohn theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT camillatøndel theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT bjørnblomberg theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT maichitrieu theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT ninalangeland theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT rebeccajanecox theperformancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT heidisyre performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT mariuseduardobraobreque performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT ingvilddalen performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT asegarløvriis performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT aseberg performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT irenhøylandlohr performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT jonsundal performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT larskarekleppe performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT maysisselvadla performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT oleberntlenning performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT janstefanolofsson performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT kristingreveisdahlmohn performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT camillatøndel performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT bjørnblomberg performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT maichitrieu performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT ninalangeland performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection AT rebeccajanecox performancesofthreecommerciallyavailableassaysforthedetectionofsarscov2antibodiesatdifferenttimepointsfollowingsarscov2infection |